uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~

~ Data to be presented today at Epilepsy Therapies & Diagnostics Development Symposium (ETDD) ~

Read more at globenewswire.com